Symbols / RNXT
RNXT Chart
About
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 33.35M |
| Enterprise Value | 23.54M | Income | -11.11M | Sales | 928.00K |
| Book/sh | 0.22 | Cash/sh | 0.27 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | -3.37 | PEG | — |
| P/S | 35.94 | P/B | 4.14 | P/C | — |
| EV/EBITDA | — | EV/Sales | 25.37 | Quick Ratio | 5.42 |
| Current Ratio | 5.83 | Debt/Eq | 2.92 | LT Debt/Eq | — |
| EPS (ttm) | -0.36 | EPS next Y | -0.27 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -68.39% |
| ROE | -146.61% | ROIC | — | Gross Margin | 67.78% |
| Oper. Margin | -12.03% | Profit Margin | 0.00% | Shs Outstand | 36.65M |
| Shs Float | 32.52M | Short Float | 1.59% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 1.45 | 52W Low | 0.70 |
| Beta | 1.31 | Avg Volume | 241.56K | Volume | 113.01K |
| Target Price | $6.69 | Recom | Strong_buy | Prev Close | $0.90 |
| Price | $0.91 | Change | 0.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.69
Mean price target
2. Current target
$0.91
Latest analyst target
3. DCF / Fair value
$-3.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.91
Low
$2.75
High
$13.00
Mean
$6.69
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-11-21 | main | Ascendiant Capital | Buy → Buy | $13 |
| 2025-08-25 | main | Ascendiant Capital | Buy → Buy | $12 |
| 2025-06-05 | main | Ascendiant Capital | Buy → Buy | $12 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-04-28 | main | Ascendiant Capital | Buy → Buy | $11 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-27 | init | HC Wainwright & Co. | — → Buy | $3 |
| 2024-12-10 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2024-09-12 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2024-06-17 | init | Ascendiant Capital | — → Buy | $8 |
| 2024-02-02 | init | Alliance Global Partners | — → Buy | $4 |
| 2023-11-15 | down | Maxim Group | Buy → Hold | — |
| 2023-08-18 | main | Roth MKM | Buy → Buy | $13 |
| 2021-11-01 | init | Roth Capital | — → Buy | $16 |
| 2021-10-06 | init | Maxim Group | — → Buy | $15 |
- How real-time pressure readings could sharpen chemo targeting - Stock Titan Wed, 04 Feb 2026 08
- $RNXT stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 08 Jan 2026 08
- Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation - simplywall.st Sat, 16 Aug 2025 07
- RenovoRx (RNXT): Analyst Raises Price Target Following Positive Outlook | RNXT Stock News - GuruFocus ue, 17 Feb 2026 11
- RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance hu, 14 Aug 2025 07
- Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail hu, 19 Feb 2026 12
- Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com Mon, 22 Dec 2025 08
- New Analyst Forecast: $RNXT Given $12.5 Price Target | RNXT Stock News - Quiver Quantitative Mon, 24 Nov 2025 08
- RenovoRx (Nasdaq: RNXT) to Share RenovoCath, $900K YTD Revenue at AGP Showcase - Stock Titan Wed, 19 Nov 2025 08
- Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term - Yahoo Finance Sun, 18 Jan 2026 08
- RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance - The Globe and Mail Sat, 03 Jan 2026 08
- Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com Mon, 08 Dec 2025 08
- Insider Purchase: Chief Medical Officer of $RNXT Buys 12,000 Shares - Quiver Quantitative Wed, 17 Dec 2025 08
- Chemo-delivery device now used at nine U.S. cancer centers - Stock Titan ue, 20 Jan 2026 08
- RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance Wed, 12 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 9975 | — | Purchase at price 1.00 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2026-01-21 00:00:00 | D |
| 1 | 9795 | 8424 | — | Purchase at price 0.86 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2025-12-31 00:00:00 | D |
| 2 | 205 | 169 | — | Purchase at price 0.83 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2025-12-30 00:00:00 | D |
| 3 | 5000 | 4506 | — | Purchase at price 0.90 per share. | BAGAI SHAUN R. | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 4 | 5000 | 4262 | — | Purchase at price 0.85 per share. | BAGAI SHAUN R. | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
| 5 | 12000 | 10200 | — | Purchase at price 0.85 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2025-12-16 00:00:00 | D |
| 6 | 10000 | 9600 | — | Purchase at price 0.96 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2025-12-05 00:00:00 | D |
| 7 | 22000 | 17600 | — | Purchase at price 0.80 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2025-11-24 00:00:00 | D |
| 8 | 10000 | 9296 | — | Purchase at price 0.91 - 0.95 per share. | BAGAI SHAUN R. | Chief Executive Officer | — | 2025-08-25 00:00:00 | D |
| 9 | 21000 | 29400 | — | Purchase at price 1.40 per share. | AGAH RAMTIN M.D. | Officer and Director | — | 2025-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.74M | -13.11M | -9.94M | -5.54M |
| TotalUnusualItems | 1.77M | 1.71M | 0.00 | 62.00K |
| TotalUnusualItemsExcludingGoodwill | 1.77M | 1.71M | 0.00 | 62.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.81M | -10.23M | -9.89M | -6.32M |
| ReconciledDepreciation | 0.00 | 6.00K | 9.00K | |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | -10.97M | -11.40M | -9.94M | -5.48M |
| EBIT | -10.97M | -11.40M | -9.95M | -5.49M |
| NetInterestIncome | 384.00K | -545.00K | 57.00K | -834.00K |
| InterestExpense | 834.00K | |||
| InterestIncome | 57.00K | |||
| NormalizedIncome | -10.59M | -11.94M | -9.89M | -6.39M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.81M | -10.23M | -9.89M | -6.32M |
| TotalExpenses | 11.01M | 11.40M | 9.95M | 5.67M |
| TotalOperatingIncomeAsReported | -10.97M | -11.40M | -9.95M | -5.67M |
| DilutedAverageShares | 22.27M | 10.29M | 9.05M | 5.22M |
| BasicAverageShares | 22.27M | 10.29M | 9.05M | 5.22M |
| DilutedEPS | -0.40 | -0.99 | -1.09 | -1.21 |
| BasicEPS | -0.40 | -0.99 | -1.09 | -1.21 |
| DilutedNIAvailtoComStockholders | -8.81M | -10.23M | -9.89M | -6.32M |
| NetIncomeCommonStockholders | -8.81M | -10.23M | -9.89M | -6.32M |
| NetIncome | -8.81M | -10.23M | -9.89M | -6.32M |
| NetIncomeIncludingNoncontrollingInterests | -8.81M | -10.23M | -9.89M | -6.32M |
| NetIncomeContinuousOperations | -8.81M | -10.23M | -9.89M | -6.32M |
| PretaxIncome | -8.81M | -10.23M | -9.89M | -6.32M |
| OtherIncomeExpense | 1.77M | 1.71M | 4.00K | 181.00K |
| OtherNonOperatingIncomeExpenses | 4.00K | 119.00K | ||
| SpecialIncomeCharges | 0.00 | 62.00K | ||
| OtherSpecialCharges | -62.00K | |||
| GainOnSaleOfSecurity | 1.77M | 1.71M | ||
| NetNonOperatingInterestIncomeExpense | 384.00K | -545.00K | 57.00K | -834.00K |
| TotalOtherFinanceCost | -384.00K | 545.00K | -57.00K | 834.00K |
| InterestExpenseNonOperating | 834.00K | |||
| InterestIncomeNonOperating | 57.00K | |||
| OperatingIncome | -10.97M | -11.40M | -9.95M | -5.67M |
| OperatingExpense | 11.01M | 11.40M | 9.95M | 5.67M |
| ResearchAndDevelopment | 6.03M | 5.67M | 4.30M | 3.04M |
| SellingGeneralAndAdministration | 4.99M | 5.73M | 5.65M | 2.63M |
| GeneralAndAdministrativeExpense | 4.99M | 5.73M | 5.65M | 2.63M |
| OtherGandA | 2.30M | 3.26M | 3.73M | 1.63M |
| SalariesAndWages | 2.69M | 2.47M | 1.92M | 998.00K |
| GrossProfit | 43.00K | 0.00 | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 43.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 43.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 24.03M | 10.69M | 9.10M | 8.93M |
| ShareIssued | 24.03M | 10.69M | 9.10M | 8.93M |
| TotalDebt | 278.00K | 0.00 | ||
| TangibleBookValue | 4.48M | -3.00M | 6.16M | 15.35M |
| InvestedCapital | 4.48M | -3.00M | 6.16M | 15.35M |
| WorkingCapital | 5.92M | 291.00K | 6.16M | 15.34M |
| NetTangibleAssets | 4.48M | -3.00M | 6.16M | 15.35M |
| CapitalLeaseObligations | 278.00K | 0.00 | ||
| CommonStockEquity | 4.48M | -3.00M | 6.16M | 15.35M |
| TotalCapitalization | 4.48M | -3.00M | 6.16M | 15.35M |
| TotalEquityGrossMinorityInterest | 4.48M | -3.00M | 6.16M | 15.35M |
| StockholdersEquity | 4.48M | -3.00M | 6.16M | 15.35M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 0.00 | 17.00K | 0.00 |
| OtherEquityAdjustments | 17.00K | |||
| RetainedEarnings | -50.22M | -41.41M | -31.17M | -21.28M |
| AdditionalPaidInCapital | 54.70M | 38.40M | 37.32M | 36.63M |
| CapitalStock | 2.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 2.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.64M | 4.47M | 1.10M | 938.00K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.73M | 3.29M | 0.00 | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 1.52M | 3.29M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 212.00K | 0.00 | ||
| LongTermCapitalLeaseObligation | 212.00K | 0.00 | ||
| CurrentLiabilities | 1.91M | 1.18M | 1.10M | 938.00K |
| CurrentDebtAndCapitalLeaseObligation | 66.00K | |||
| CurrentCapitalLeaseObligation | 66.00K | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 817.00K | 75.00K | 475.00K | 33.00K |
| PayablesAndAccruedExpenses | 1.03M | 1.10M | 627.00K | 905.00K |
| CurrentAccruedExpenses | 440.00K | 539.00K | 93.00K | 380.00K |
| InterestPayable | 0.00 | |||
| Payables | 586.00K | 561.00K | 534.00K | 525.00K |
| AccountsPayable | 586.00K | 561.00K | 534.00K | 525.00K |
| TotalAssets | 8.12M | 1.47M | 7.26M | 16.29M |
| TotalNonCurrentAssets | 290.00K | 0.00 | 0.00 | 6.00K |
| NonCurrentPrepaidAssets | 0.00 | |||
| NetPPE | 290.00K | 0.00 | 0.00 | 6.00K |
| AccumulatedDepreciation | 0.00 | 0.00 | ||
| GrossPPE | 290.00K | 0.00 | 0.00 | 6.00K |
| Leases | 0.00 | 6.00K | ||
| OtherProperties | 278.00K | |||
| MachineryFurnitureEquipment | 12.00K | 0.00 | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 7.83M | 1.47M | 7.26M | 16.28M |
| OtherCurrentAssets | 303.00K | 24.00K | 825.00K | 1.09M |
| CurrentDeferredAssets | 0.00 | 101.00K | 0.00 | |
| PrepaidAssets | 328.00K | 168.00K | 1.09M | |
| Receivables | 43.00K | 0.00 | ||
| AccountsReceivable | 43.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 7.15M | 1.17M | 6.44M | 15.19M |
| OtherShortTermInvestments | 0.00 | 2.05M | 0.00 | |
| CashAndCashEquivalents | 7.15M | 1.17M | 4.39M | 15.19M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.14M | -10.26M | -8.81M | -5.93M |
| IssuanceOfDebt | 0.00 | 1.98M | ||
| IssuanceOfCapitalStock | 15.02M | 5.00M | 0.00 | 14.56M |
| CapitalExpenditure | -12.00K | -15.00K | ||
| InterestPaidSupplementalData | 21.00K | 14.00K | ||
| IncomeTaxPaidSupplementalData | 2.00K | 38.00K | ||
| EndCashPosition | 7.15M | 1.17M | 4.39M | 15.19M |
| BeginningCashPosition | 1.17M | 4.39M | 15.19M | 1.79M |
| ChangesInCash | 5.98M | -3.22M | -10.80M | 13.40M |
| FinancingCashFlow | 15.12M | 5.01M | 42.00K | 19.33M |
| CashFlowFromContinuingFinancingActivities | 15.12M | 5.01M | 42.00K | 19.33M |
| ProceedsFromStockOptionExercised | 102.00K | 8.00K | 42.00K | 2.79M |
| NetCommonStockIssuance | 15.02M | 5.00M | 0.00 | 14.56M |
| CommonStockIssuance | 15.02M | 5.00M | 0.00 | 14.56M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.98M | ||
| NetLongTermDebtIssuance | 0.00 | 1.98M | ||
| LongTermDebtIssuance | 0.00 | 1.98M | ||
| InvestingCashFlow | -12.00K | 2.03M | -2.03M | -15.00K |
| CashFlowFromContinuingInvestingActivities | -12.00K | 2.03M | -2.03M | -15.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 2.03M | -2.03M | 0.00 |
| SaleOfInvestment | 0.00 | 2.03M | 5.97M | 0.00 |
| PurchaseOfInvestment | 0.00 | -8.00M | 0.00 | |
| NetPPEPurchaseAndSale | -12.00K | 0.00 | ||
| PurchaseOfPPE | -12.00K | 0.00 | ||
| CapitalExpenditureReported | 0.00 | -15.00K | ||
| OperatingCashFlow | -9.12M | -10.26M | -8.81M | -5.92M |
| CashFlowFromContinuingOperatingActivities | -9.12M | -10.26M | -8.81M | -5.92M |
| ChangeInWorkingCapital | 280.00K | 605.00K | 428.00K | -265.00K |
| ChangeInOtherCurrentAssets | -221.00K | -101.00K | 9.00K | 4.00K |
| ChangeInPayablesAndAccruedExpense | 661.00K | 73.00K | 155.00K | 705.00K |
| ChangeInAccruedExpense | 636.00K | 46.00K | 155.00K | 342.00K |
| ChangeInInterestPayable | 0.00 | |||
| ChangeInPayable | 25.00K | 27.00K | 9.00K | 363.00K |
| ChangeInAccountPayable | 25.00K | 27.00K | 0.00 | 363.00K |
| ChangeInPrepaidAssets | -160.00K | 633.00K | 264.00K | -970.00K |
| OtherNonCashItems | 7.00K | 697.00K | ||
| StockBasedCompensation | 1.17M | 1.08M | 644.00K | 147.00K |
| DepreciationAmortizationDepletion | 0.00 | 6.00K | 9.00K | |
| DepreciationAndAmortization | 0.00 | 6.00K | 9.00K | |
| Depreciation | 0.00 | 6.00K | 9.00K | |
| OperatingGainsLosses | -1.77M | -1.71M | -180.00K | |
| GainLossOnInvestmentSecurities | -1.77M | -1.71M | -118.00K | |
| NetIncomeFromContinuingOperations | -8.81M | -10.23M | -9.89M | -6.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RNXT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|